UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - BIOSPECIFICS TECHNOLOGIES CO ownership

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of BIOSPECIFICS TECHNOLOGIES CO
ValueSharesWeighting
Q4 2020$203,550,0002,3000.00%
Other shareholders
BIOSPECIFICS TECHNOLOGIES CO shareholders Q2 2024
NameSharesValueWeighting ↓
APIS CAPITAL ADVISORS, LLC 36,000$2,244,0002.71%
JW Asset Management, LLC 73,649$4,591,0002.36%
THB ASSET MANAGEMENT 87,491$5,453,0000.79%
RICE HALL JAMES & ASSOCIATES, LLC 315,972$19,695,0000.63%
EAM Global Investors LLC 22,789$1,420,0000.63%
Elk Creek Partners, LLC 73,936$4,608,0000.33%
Matarin Capital Management, LLC 69,964$4,361,0000.32%
EAM Investors, LLC 17,696$1,103,0000.27%
CADENCE CAPITAL MANAGEMENT LLC 37,196$2,318,0000.21%
Cavalier Investments, LLC 7,800$486,0000.20%
View complete list of BIOSPECIFICS TECHNOLOGIES CO shareholders